A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 63
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PCV
Long Form : penciclovir
No. Year Title Co-occurring Abbreviation
2019 Synthesis and anti-HSV activity of tricyclic penciclovir and hydroxybutylguanine derivatives. HBG
2018 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains. aa, ACV, BAC, CPE, HSV-2, TK
2016 Antiherpetic Plants: A Review of Active Extracts, Isolated Compounds, and Bioassays. ACV, HSV-1
2016 Cutaneous biodistribution of ionizable, biolabile aciclovir prodrugs after short duration topical iontophoresis: Targeted intraepidermal drug delivery. ACV
2014 Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. ACV, BVDU, FOS, HSV
2013 Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. ACV, VACV, VDB, VZV
2013 Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective. ACV, HSV
2011 Biotransformation of the antiviral drugs acyclovir and penciclovir in activated sludge treatment. ACV, Carboxy-ACV, SS, TPs
2011 Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. ACV, HSV, TK
10  2010 Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity. CdG, GCV
11  2010 Testing of herpes simplex virus for resistance to antiviral drugs. ACV, FOS, HSV, HSV-1, pol, TK
12  2009 Characterization of a spontaneous drug-resistant mutant of monkey B virus (Macacine herpesvirus 1). TK
13  2008 Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds. ACV, CDV, FHV-1
14  2008 Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase. ACV, CDV, FHV-1, HSV-1, MOI, TK
15  2008 Substrate specificity and molecular modelling of the feline herpesvirus-1 thymidine kinase. ACV, EHV-4, FHV-1, GCV, TK
16  2006 Inhibitory efficacy of cyclosal-nucleoside monophosphates of aciclovir and brivudin on DNA synthesis of orthopoxvi ruses. ACV, BVDU, cycloSal-MP
17  2006 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1. ACV, GCV, HSV-1, Thd, vTK
18  2005 Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. FEAU, FIAU, FMAU, HSV1-tk
19  2005 In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses. ACV, BVDU
20  2005 Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses. ACV, BVDU, CDV, HSV-1, TK, VZV
21  2004 Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. ACV, BVdU, FHV-1, HPMPA, TFT
22  2004 In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? ACV, BVDU, HEL, HPMPA, PFA, PME, TK, VZV
23  2003 Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection. FHBG, FIAU
24  2003 Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. ACV, DNApol, HSV-1, TK
25  2002 Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. ACV, DSBs, GCV, SCGE, SSBs
26  2002 Comparison of methods for identifying resistant herpes simplex virus and measuring antiviral susceptibility. ACV, PAR, PEA, PRA
27  2002 Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis. ACV
28  2002 Studies on the thermal decomposition process and kinetics of purine drugs. ACV
29  2002 Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. ACV, HSV
30  2002 The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase. ACV, dCyd, GCV, HSV-1, LBV
31  2001 Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. ACV, HSV, HSV-1, TK
32  2001 Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells. ACV, GCV, HSV-TK
33  2001 Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. BVdU, EBV, GCV, PT, TK
34  2000 Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. HBV
35  2000 Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. GCV, HSV-1, TK
36  2000 Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2. ACV, HSV, HSV-1, TK
37  2000 Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs. ACV, ACVMP
38  2000 Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. DAPD, FLG, LBV, MMF
39  2000 The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. 3TCTP, ADV, dCTP, Flu, FOS, GCV, HBV, HU, LCV, MTX
40  1999 Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes. ACV, HSV-2
41  1999 Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. ACV, ADV, CDV, CPE, GCV, H2G, HSV-1, LBV, TK
42  1999 Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. ACV, HSV, IC
43  1999 Selective activity of various antiviral compounds against HHV-7 infection. ACV, ATA, BVDU, DS, GCV, HHV-7, PAVAS, PF4, PFA, PMEA, PMPA, PS, PVAS, SDF-1alpha
44  1999 Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. HBV, L-FMAU, PMEA
45  1999 Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation. DIG, LBV, PCR
46  1998 Antiherpesvirus activities of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl]guanine (A-5021) in cell culture. ACV, HEL
47  1998 Chemistry and anti-herpes simplex virus type 1 evaluation of cycloSal-nucleotides of acyclic nucleoside analogues. ACV, cPCVMP, HSV-1, MP, T-PCV
48  1998 Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. ACV, HSV-1, TKs, VZV
49  1998 The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. ACV, GCV, HSV, MMF
50  1997 Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. ACV, GCV, HCMV, ORF, rVV, TK
51  1996 Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, acyclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. ACV, CAF, GCV, MNPCE
52  1996 Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. ACV, FCV, GCV, SCE, VACV
53  1996 Famciclovir for treatment of herpesvirus infections. ---
54  1996 Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. dGTP, HBV, PCV-TP, pol-RT
55  1995 Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. ACV, ANP, BCV, BVDU, FACS, GCV, HCMV, HHV-6
56  1995 Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. ACV, BVDU, GCV, PAA, VZV
57  1995 Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. ACV, EC50, VZV
58  1994 Chemotherapy of varicella zoster virus infections. ACV, AIDS, FCV, TK, VZV
59  1993 Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. ACV
60  1993 Sequence analysis of thymidine kinase-defective mutants of equine herpesvirus-1 (EHV-1). EHV-1, TK
61  1993 Use of isotopically chiral [4'-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase. PCV-TP
62  1992 In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2. HSV
63  1992 The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. EHV-1